[PL]For the Sustainable Development of the Pharmaceutical Society of Japan
○Yoshiharu Iwabuchi1(1. Grad. Sch. Pharm Sci., Tohoku Univ.)
The 143rd Annual Meeting of the Pharmaceutical Society of Japan (Sapporo)
Mar 25 - Mar 28, 2023HOKKAIDO UNIVERSITY
You can search for presentations in this event.
Search
The 143rd Annual Meeting of the Pharmaceutical Society of Japan (Sapporo)
Mar 25 - Mar 28, 2023HOKKAIDO UNIVERSITY
You can search for presentations in this event.
SearchSearch Results(4,223)
[SL01]疾患進行、臨床的治療、薬物動態の帰結を予測するための新しい技術
○Akihiro Hisaka1(1. Chiba Univ.)
[SL02]Translational Natural Product Research
○Xiaoguang Lei1(1. Dep. Chem. Biol., College of Chem. and Mol. Eng., Peking Univ.)
[SL03]Dynamics of Function and Regulation of the Endoplasmic Reticulum
○Kazutoshi Mori1(1. Graduate School of Science, Kyoto Univ.)
[SL04]Design of lipid nanoparticles that enable gene therapies
○Pieter Cullis1(1. Dept. Biochemistry & Molecular Biology, Fac. Medicine, Univ. British Columbia)
[SL05]Microplastic-mediated exposure of plastic additives
○Hideshige Takada1(1. Tokyo Univ. Agric. Technol., Facl. Agric.)
[SL06]Ribosomal peptides: hidden gifts of Nature
○Jörn Piel1(1. Inst. Microbiol., ETH Zurich)
[SL07]25 years since the cloning of capsaicin receptor TRPV1 - Ｒｅａｒｃｈ on thermosensitive TRP channels, present and future -
○Makoto Tominaga1,2(1. Div. Cell Signaling, National Institute for Physiological Sciences, 2. Thermal Biology Group, Exploratory Research Center on Life and Living Systems)
[SL08]Physiological implications and pharmacological applications of Anoctamins
○Uhtaek Oh1(1. Brain Sci Inst, Korea Inst of Sci Tech (KIST))
[SL09]Near infrared photoimmunotherapy of cancer
○Hisataka Kobayashi1(1. Molecular Imaging Branch, NCI/NIH)
[SL10]Endoribonuclease Regnase-1 involved in regulation of inflammation, immunity and metabolism
○Shizuo Akira1(1. IFReC, Osaka University)
[SL11]Immune response to, and regulation by, extracellular nucleic acids
○Ken Ishii1(1. The Institute of Medical Science,The University of Tokyo)
[SL12]Nucleic acid derivatives for the development of oligonucleotide therapeutics
○Satoshi Obika1,2,3(1. Grad. Sch. Pharm. Sci., Osaka Univ., 2. OTRI, Osaka Univ., 3. NIBIOHN)
[EL01]Utilization of medical big data under The Next Generation Medical Infrastructure Act
○Hidetaka Nishimura1(1. National Healthcare Policy Secretariat, Government of Japan)
[AL01]Development of highly selective synthetic methods for supporting a sustainable society and their application to pharmaceutical sciences
○Shuji Akai1(1. Graduate School of Pharmaceutical Sciences, Osaka Univ)
[AL02]Creation of solid catalysts and development of functional group transformation methods based on the excavation of potential catalytic activity
○Hironao Sajiki1(1. Gifu Pharm. Univ.)
[AL03]Novel gene/nucleic acids delivery system based on controlled intracellular trafficking and its application to nanomedicine
○Hideyoshi Harashima1(1. Hokkaido Univ. Fac. Pharm. Sci.)
[AL04]Novel strategies for the discovery of drug targets highlighting molecular mechanisms and clinical evidence
○Shuji Kaneko1(1. Kyoto Univ. Grad. Sch. Pharm. Sci.)
[AL05]Drug delivery systems for improvement of biopharmaceutical properties
○Satomi Onoue1(1. Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka)
[AL06]Development of therapeutic agents for severe infections that target vascular permeability
○Yoshiaki Okada1(1. Grad. Sch. Pharm. Sci., Osaka Univ.)
[AL07]Physiological and pathological significance of chloride channels
○Hisao Yamamura1(1. Grad. Sch. Pharma. Sci., Nagoya City Univ.)
[AL08]Development of imaging and therapeutic agents based on nuclear and optical technologies
○Mikako Ogawa1(1. Faculty of Pharm Sci, Hokkaido Univ.)
[AL09]X-ray crystal structure analysis and engineering of key enzymes responsible for the biosynthesis of plant active components
○Hiroyuki Morita1(1. INM, Univ. Toyama)
[AL10]Development and application of low-molecular-weight gelators based on urea derivatives
○Masamichi Yamanaka1(1. Meiji Pharm. Univ.)
[AL11]Metabolic alteration analyses of endogenous metabolites and diagnostic biomarker searching for various diseases using liquid chromatography and mass spectrometry
○Masamitsu Maekawa1(1. Dept. Pharm. Sci., Tohoku Univ. Hosp.)
[AL12]Drug discovery research for brain injury focused on functional molecules in astrocytes
○Shotaro Michinaga1(1. Meiji Pharm Univ.)
[AL13]Integrative research of neuropharmacology and informatics pharmacology for mental disorder
○Kazuki Nagayasu1(1. Grad. Sch. Pharm. Sci., Kyoto Univ.)
[AL14]Elucidation of mechanism underlying individual differences in adverse drug reactions
○Shigeki Aoki1(1. Grad. Sch. Pharm. Sci., Chiba Univ.)
[AL15]Mechanistic investigation of natural product biosynthesis by theoretical and computational chemistry
○Hajime Sato1,2,3(1. Interdiscip. Grad. Sch. Med. Eng. Univ. Yamanashi, 2. JST PRESTO, 3. MEXT LEADER)
[AL16]Development of novel synthetic methods focusing on structural properties and application to natural product synthesis
○Kazutada Ikeuchi1(1. Grad. Sch. Pharm. Sci., Nagoya City Univ.)
[AL17]Development of methods to generate radical species and synthetic applications
○Masaya Nakajima1(1. Graduate School and Faculty of Pharmaceutical Sciences, Chiba University)
[AL18]Application of cell adhesive peptides to biomaterials
○Yuji Yamada1(1. Tokyo Univ. Pharm. Life. Sci.)
[AL19]Development of methods to detect of substandard and falsified medicines based on clarifying their pharmaceutical characteristics by applying modern technology
○Naoko Yoshida1(1. ai@ku, Kanazawa Univ.)
[AL20]Development of an improved adenovirus vector and its application to the treatment of lifestyle-related diseases
○Kahori Shimizu1(1. Pharma., Osaka Ohtani Univ.)
[AL21]The discovery of a novel siderophore cephalosporin cefiderocol
○Toshiaki Aoki1, Kenji Yamawaki2, Takafumi Sato2, Yasuhiro Nishitani2, Yoshinori Yamano2(1. Administration Division, SHIONOGI & Co. Ltd., 2. Research Division, SHIONOGI & CO., LTD.)
[AL22]Discovery of a JAK Inhibitor: delgocitinib
○Makoto Shiozaki1, Satoru Noji1, Noriko Konishi1, Atsuo Tanimoto1, Yuichi Naka1(1. JAPAN TOBACCO INC.)
[AL23]Contribution to pharmacy/pharmacist education through writing
○Hideaki Natsugari1(1. NIIGATA UNIVERSITY OF PHARMACY AND MEDICAL AND LIFE SCIENCES (NUPALS))
[AL24]Metals and Peptides and Polymers, Oh My! Following the Yellow Brick Road Towards a Universal Influenza Vaccine
○Kristy M. Ainslie1(1. UNC Eshelman School of Pharmacy)
[ISS01-01]Design and synthesis of novel κ opioid receptor agonist without sedative effect
○Tsuyoshi Saitoh1,2, Keita Kajino3, Masahiro Yata3, Akihisa Tokuda2, Yasuyuki Nagumo1, Hiroshi Nagase1,3(1. IIIS, Univ. Tsukuba, 2. Grad. Sch. Comp. Hum. Sci., Univ. Tsukuba, 3. Grad. Sch. Pure Appl. Sci., Univ. Tsukuba)
[ISS01-02]New mechanism underlying the chronicity of pain caused by nerve damage
○Makoto Tsuda1(1. Grad. Sch. Pharm. Sci., Kyushu Univ.)
[ISS01-03]Optimization of PDE4 Inhibitors for Topical Application - Difamilast, A Novel Therapeutic Agent for Atopic Dermatitis -
○Hidetaka Hiyama1, Naoya Arichika1, Masafumi Shibamori1(1. Otsuka Pharmaceutical)
[ISS01-04]MRG family GPCRs as novel itch-sensing receptors
○Junken Aoki1, Yugo Takagi1, Jumpei Omi1(1. Graduate School of Pharmaceutical Sciences)
[ISS01-05]Towards drug discovery based on the 3D-structures of prostaglandin receptors
○Takuya Kobayashi1(1. Kansai Medical University)
[ISS01-06]Application of thermosensitive TRP channels for development of cosmetics
○Fumitaka Fujita1,2,3(1. Graduate School of Pharmaceutical Sciences, Osaka University, 2. Mandom Corporation, 3. Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences)
[ISS01-07]TRP channels mediate visceral hypersensitivity during intestinal inflammation
○Kenjiro Matsumoto1, Shinichi Kato1(1. Kyoto Pharm Univ)
[ISS01-08]Mechanism and treatment strategy of chemotherapy-induced peripheral neuropathy
○Takayuki Nakagawa1(1. Dept Clin Pharmacol Ther, Kyoto Univ Hospital)
[ISS02-01]Research and development of novel antibody-drug conjugate, DXd-ADC technology
○Toshinori Agatsuma1(1. Daiichi Sankyo)
[ISS02-02]Antibody Therapeutics and Engineering
○Kohei Tsumoto1,2(1. Sch Eng, Univ Tokyo, 2. Inst Med Sci, Univ Tokyo)
[ISS02-03]Regulatory science for therapeutic monoclonal antibodies aimed at promoting the immunogenicity risk management
○Akiko Ishii-Watabe1, Hiroko Shibata1, Minoru Tada1(1. NIHS)
[ISS02-04]The past, present and future of immune checkpoint inhibitor anti-PD-1 antibody, nivolumab.
○Takao Yoshida1(1. Research Center of Oncology, Ono Pharmaceutical)
4,223 results ( 1 - 50 )
- 1
- ...